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Summary 
An anonymous web-based survey of alpaca owners was used to learn more about the 
clinical presentation, diagnosis, and treatment of coccidioidomycosis in alpacas in the United 
States. Thirty-seven owners, with 1,117 alpacas, completed the survey. Over 4% of alpacas 
included in the study were diagnosed with coccidioidomycosis between 2005 and 2016 (5 post 
mortem, 46 clinically). Immunodiffusion titers ranged from 1:4 to ≥ 1:256 in sick animals. 
Alpacas residing in Arizona counties with a high incidence of human disease were 5.8 times 
more likely to contract coccidioidomycosis than animals residing in other areas of the state. 
Treatment was reported in 23 alpacas, and 78% of those animals died or were euthanized. 
Necropsy records from a veterinary diagnostic laboratory in Tucson, AZ were reviewed to 
estimate the severity of disease in this species. Nine cases identified for review died of 
disseminated coccidioidomycosis; the disease was extensive in most animals, with lungs, lymph 
nodes and liver most frequently affected. Alpacas appear to be highly susceptible to severe 
illness as a result of infection by Coccidioides spp., frequently resulting in death. More research 
is needed to better understand the epidemiology, clinical signs, and treatment protocols for 
coccidioidomycosis in alpacas. 
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Introduction 
Coccidioidomycosis, or Valley Fever, is an infectious fungal disease caused by 
Coccidioides immitis or C. posadasii. The Coccidioides spp. are endemic to parts of the Western 
Hemisphere, including the southwestern United States and northern Mexico and scattered 
regions in Central and South America. Areas in the United States considered endemic include 
regions of Arizona, California, New Mexico, southern Nevada and Utah, and Texas (Laniado-
Laborin, 2007). Recently, the fungus was found in the soil of an area in eastern Washington state 
after three human cases were identified (A. P. Litvintseva et al., 2015). Domestic livestock such 
as cattle and sheep are susceptible to infection, although clinical illness is rare. South American 
camelids (SAC), on the other hand, appear to be prone to widespread disseminated illness 
(Fernandez, Hidalgo, Hodzic, Diab, & Uzal, 2018; Shubitz, 2007).    
The life cycle of Coccidioides occurs in two distinct phases. In the soil, the hyphal form 
grows during the rainy season. As the soil dries out, the hyphae form into arthroconidia, which 
are dispersed through wind or other soil disruption. Infection is typically through inhalation, and 
this initial respiratory infection ranges from asymptomatic to severe. In the body, arthroconidia 
transform into spherules which develop internal endospores. When the spherules rupture, 
endospores may disseminate to nearly any location in the body. The presentation of the 
disseminated disease is variable as clinical signs will relate to the organ affected (Nguyen et al., 
2013).    
There are estimated to be more than 76,000 llamas (Llama glama) and about 140,000 
alpacas (Vicugna pacos) in the United States (Vilsack & Clark, 2014). An estimated nearly 
20,000 alpacas live in the region endemic for Coccidioides spp. South American camelids appear 
to be prone to development of widespread, often fatal, disease due to Coccidioides spp. based on 
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reports in llamas plus conversations with pathologists, veterinarians, and animal owners in 
southern Arizona (Coster, Ramos-Vara, Vemulapalli, Stiles, & Krohne, 2010; Fowler, 
Pappagianis, & Ingram, 1992; Maddy, 1959; Muir & Pappagianis, 1982). A review of necropsies 
performed on camelids in California between 1992 and 2013 found that 4% of the animals died 
from coccidioidomycosis; the fungus was found in extrapulmonary tissue in most of these 
animals (Fernandez et al., 2018). There is one case report of coccidioidomycosis causing 
spontaneous abortion in an alpaca with infection of the placenta and fetus. The dam also tested 
positive for coccidioidomycosis with a titer of 1:256 and was euthanized. Upon necropsy, she 
was found to have disseminated disease in multiple organs, including the uterus (Diab et al., 
2013). However, information about the infection and mortality rate is scant for both alpacas and 
llamas. The purpose of this study was to obtain more information about the frequency, clinical 
signs, treatment, and outcome of coccidioidomycosis in alpacas. Secondarily, we reviewed 
necropsy reports from Arizona Veterinary Diagnostic Laboratory (Tucson, AZ) and cataloged 
the extent of disease in alpacas that died of coccidioidomycosis. 
Materials and Methods  
Survey data were collected and managed using REDCap electronic data capture tools 
hosted at The University of Arizona (Harris et al., 2009). A public, anonymous, web-based 
survey collected data about the number, location, and housing of alpacas. Respondents were 
asked to report whether one or more of their animals had been definitively diagnosed with 
coccidioidomycosis by a veterinarian between 2005 and 2016. Those with diagnosed animals 
were then asked for additional information about the clinical signs, diagnostic tests, treatment, 
and outcome.  
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 The Alpaca Breeders of Arizona association dispersed the link to the survey to their 
members and all were encouraged to share the link with other alpaca owners wherever they 
lived. Some respondents informed the investigators that they also used social media to disperse 
the survey link. Additionally, a link to the survey was provided on the Valley Fever Center for 
Excellence’s webpage and Facebook page.  
 The database of Arizona Veterinary Diagnostic Laboratory was searched for 
coccidioidomycosis in alpacas. Cases that were serological submissions only were not utilized.  
Records were reviewed for cases with cytological or tissue specimens or complete necropsies. 
Statistical analysis 
 Data were exported to IBM SPSS Statistics for Windows, version 24 (IBM Corp., 
Armonk, N.Y., USA) for analysis. Frequencies and means were calculated. An odds ratio was 
calculated to determine the risk of clinical illness by location. Due to the small sample size, a 
Fisher’s exact test was used to analyze the risk of housing animals on a dry lot. All assumptions 
for the Fisher’s exact test were met. Significance was set at 0.05.   
Results 
 Geographic distribution of alpacas with coccidioidomycosis – The survey was open to all 
alpaca owners across the United States; in 2012 there were 9,353 alpaca farms in the country 
(Vilsack & Clark, 2014). As we distributed the survey through online resources, including a 
breeder association in Arizona, we anticipated that most responses would come from the highly 
endemic region of the country. Thirty-eight owners submitted at least partial responses to the 
survey. Only two surveys were received from areas outside the known endemic region for 
Coccidioides spp. In one case, while the alpacas were diagnosed in New Hampshire, the 
veterinarian contacted investigators to inform them that the alpacas had been imported from 
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Crane, Texas (Kitt Hollister, DVM, personal communication, 10/28/16). For the analysis, these 
two animals were considered to be Texas cases. A second survey received from an owner in New 
Jersey reported no cases of coccidioidomycosis and the herd was removed from the analysis.  
Most respondents were from Arizona (n=23, 62%), followed by California (n=7, 19%), 
New Mexico (n=5, 14%), and Texas (n=2, 5%). Reported herd size ranged from 2 to 100 alpacas 
(mean = 30.9), with a total of 1,117 alpacas. Twenty-two of the 37 owners reported having had at 
least one alpaca diagnosed with coccidioidomycosis by a veterinarian between 2005 and 2016. 
(Table 1) Owners reported a total of 51 ill animals (4.6% of all alpacas included in the survey), 
with respondents reporting between 1% and 78% of their herd having been affected with 
coccidioidomycosis (mean = 11%, SD = 17.4). The largest number of animals diagnosed with 
coccidioidomycosis in one herd originated from a respondent in Crane, Texas, reporting 18 ill 
animals with an approximate herd size of 23 alpacas. A veterinarian in that area of Texas was 
contacted and she confirmed that this attack rate was consistent with her experience with 
camelids in the region (Jessica Todia, DVM, personal communication, 11/14/16).  
Because human coccidioidomycosis is reportable in Arizona, there is relatively complete 
case rate data by county for this state, where most of the alpacas in the survey resided. The 
Arizona respondents represented about 10% of the farms in the state, which was greater than the 
other states (California: 1.5%, New Mexico: 7%, Texas: 0.05%). Therefore, odds of diagnosis by 
location was only performed on the Arizona herds. Arizona counties with a high incidence of 
human disease (greater than 44 cases/100,000 people on average between 2010 and 2014) for 
which we had alpaca data are Maricopa, Pinal, Mohave, and Cochise ("Valley Fever: 2015 
Annual Report," 2015). Alpacas in the high incidence counties were found to have a 5.8 times 
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greater chance of contracting coccidioidomycosis compared with alpacas in other Arizona 
counties (p=0.0049).  
Thirty-one owners (84%) reported housing their alpacas exclusively on dry lots, which 
are fenced areas with no or minimal vegetative cover of the dirt. There was no significant 
difference found in the number of animals diagnosed with coccidioidomycosis when comparing 
animals on a dry lot versus other housing conditions, which included both irrigated and native 
grass pastures (p=0.0854). 
 Clinical signs and diagnostic testing – Though 51 alpacas were reported with 
coccidioidomycosis that had been diagnosed by a veterinarian according to the owners, 
respondents only supplied additional information on diagnosis method, clinical signs, and 
treatment for 23 animals. Eighteen animals were diagnosed by agar gel immunodiffusion, the 
standard blood test used in animals for Coccidioides species (Sykes, 2014). Six owners supplied 
additional anticoccidioidal antibody titer details. Two animals had a titer of 1:128, and there was 
one animal each with titers of 1:4, 1:32, 1:64, and ≥1:256. The other five animals were diagnosed 
through a necropsy. One of those animals had no clinical signs prior to death. 
A list of anticipated clinical signs was developed from reports in the literature (Fowler et 
al., 1992; Muir & Pappagianis, 1982). Owners were asked to select from a pick list the clinical 
signs they noted in their ill animals in the categories of respiratory disease (cough), skin disease 
(swelling or masses under the skin, non-healing sores), bone disease (lameness), polyarthritis 
(joint swelling), lymphadenopathy, CNS disease (seizures, inability to stand), and general 
malaise (fever, weight loss, decreased appetite, and decreased energy). The most frequently 
reported change in the animals was weight loss (n=15), followed by decreased energy (n=9) and 
decreased appetite (n=8). Two owners observed the loss of fiber as in their sick animals, which is 
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a previously unreported clinical finding for coccidioidomycosis in South American camelids 
(Table 2)  
 Treatment – Out of 51 animals reported as having a diagnosis of coccidioidomycosis, 
there was at least partial information regarding treatment for the same 23 animals for which 
diagnostic and clinical information were provided. Twelve alpacas were not treated, and all but 
one (92%) of them died. Five of these were the animals previously reported as having been 
diagnosed by necropsy. Six alpacas received fluconazole. Three animals (receiving either 250 or 
500 mg BID) recovered, while three on unknown dosages died. Two alpacas were put on 
ketoconazole. One of those, at an unknown dose, died, while the other, which received 1200 mg 
of ketoconazole daily, improved. For two alpacas the medication was not reported and another 
was given flunixin meglumine and antibiotics; all three of those animals died. One owner 
reported not treating the sick alpaca and the animal was stable. Of these 23 animals, 18 (78%) 
died or were euthanized, while the remaining 5 (22%) were recorded as recovered, improved, or 
stable.  
 Necropsy Findings – Records of Arizona Veterinary Diagnostic Laboratory were 
reviewed from 2007-2016, the years available in their database, for alpacas with a histological 
diagnosis of coccidioidomycosis. Up until 2016, this laboratory was the only location in Arizona 
that performed necropsies on this species. Ten animals, all submitted for necropsy, were 
identified. Of the 10, one animal died from widespread bacterial infection but had incidental 
Coccidioides spherules observed in one thoracic lymph node. Coccidioidomycosis was the stated 
cause of death of the other nine, which had abundant to florid spherules present and 
pyogranulomatous inflammation in diseased sites. Table 3 summarizes the signalment, gross, and 
histopathological findings in the cases that died from coccidioidomycosis. The median age was 
Page 9 of 20 
 
three years and gender appeared not to be a factor in these cases. All nine animals had extensive 
lung disease with severe involvement of thoracic (8/9) and cervical lymph nodes in the majority 
of animals; nodes were frequently described as abscessed and measured up to 15 cm diameter. 
Five of nine alpacas (56%) had granulomas of the heart. One of these animals also had spherules 
in the pericardium and died from right sided heart failure considered secondary to the infection. 
Finally, 5/9 animals were noted to have a thin or wasted body condition; body condition was not 
stated for three animals and only one was reported to be in good condition with adequate fat 
reserves.  
Discussion 
 There is very limited published information on coccidioidomycosis in South American 
camelids in general and on alpacas in particular, with only two publications detailing cases in 
this species, and only one animal for which there is antemortem information published (Coster et 
al., 2010; Fernandez et al., 2018). Both series reported widespread disease in most animals. This 
manuscript details findings from a web-based survey of alpaca owners, with a goal to improve 
our understanding of the scope and impact of the disease on living alpacas. Though the most 
significant limitations of the survey data are reporting by owners, lack of complete information 
for their diagnosed animals, and low response rate to the survey, the 80% reported deaths among 
23 complete cases underscores the fatality of the disease and the need for robust prospective 
research to improve diagnosis and treatment.   
In recent review of necropsy reports from the California Animal Health and Food Safety 
laboratories, coccidioidomycosis was the cause of death in 4% of camelids (alpacas and llamas) 
submitted, and 86% had extrapulmonary dissemination at the time of death (Fernandez et al., 
2018). The necropsy report does not address the number of alpacas living in the regions from 
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which the cases were submitted, nor does it address diagnosis rates among animals. We 
calculated a veterinarian-diagnosed rate of coccidioidomycosis of 4.6% from just short of 1200 
animals whose owners responded to the survey, with percentages of afflicted animals per herd 
varying from 1% to 78%. Information that was not captured in this survey but would be useful to 
understand is the serological attack rate in herds from endemic areas compared to diagnosed 
illness rates. Asymptomatic disease is common in other species (Shubitz, 2007; Shubitz, 
Butkiewicz, Dial, & Lindan, 2005), and recovery from primary respiratory illness without 
antifungal intervention is also typical in human populations (Galgiani et al., 2005). Neither this 
survey nor necropsy-based case series capture either of these infection outcomes. Thus the rate 
of coccidioidal infection in alpacas remains to be determined, preferably through systematic 
prospective studies in more than one endemic area.  
Though our report contains only a small number of animals, the high death rate of nearly 
80% of animals for which an outcome was reported (18/23) clearly demonstrates that effective 
treatment is needed. Among survey respondents, eight people reported treating animals with oral 
antifungal medication, either fluconazole or ketoconazole, but half of them died. There are no 
data on oral antifungal medication doses for alpacas, or even whether they are absorbed. In 
monogastric species afflicted by coccidioidomycosis, such as dogs, cats, and horses, orally 
administered azole antifungal medications are the backbone of treatment, and limited literature 
exists regarding pharmacokinetics of various antifungal drugs in SAC. In a study of single-dose 
oral voriconazole administration, the bioavailability of voriconazole was ~22% and the authors 
recommended doses of 20-30 mg/kg/day to achieve probable therapeutic antifungal blood levels 
(H. M. Chan, Duran, Walz, & Ravis, 2009). Similarly, other work has shown that oral 
medication bioavailability is lower in New World camelids compared to monogastric omnivores 
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(Busch et al., 1998; Kreuder et al., 2012). Phamacokinetic studies in alpacas to help determine 
appropriate therapeutic doses of oral antifungal medications would greatly aid veterinarians and 
likely improve treatment outcomes for coccidioidomycosis.  
The frequency of cardiac involvement seen in the necropsy reports was not anticipated. 
Cardiac lesions in disseminated cases of coccidioidomycosis are reported in both people and 
dogs, although with less frequency than these alpacas (O. Chan et al., 2016; Shubitz, Matz, 
Noon, Reggiardo, & Bradley, 2001), or in camelids in California (Fernandez et al., 2018). A 
similar review of canine coccidioidomycosis reports, also from Arizona Veterinary Diagnostic 
Laboratory, found that 28% had evidence of the disease in the heart and/or pericardium (Shubitz 
et al., 2001), while this population of alpacas had a rate of 56%. In the canine cases, the cardiac 
lesions were considered the likely cause of death in 11/13 dogs, while there was sufficient 
information for only 1 alpaca to determine that heart failure from cardiac coccidioidomycosis 
was at least a contributing cause of death. For the other 4 animals, there were so many sites of 
fulminant disseminated disease that the clinical significance of the cardiac lesions could not be 
determined.  
Although we were able to identify far fewer necropsy reports for alpacas with 
coccidioidomycosis compared to another review (Fernandez et al., 2018), we did identify similar 
trends. Our review identified a similar rate of dissemination to the liver (67% compared to 78%), 
and spleen and kidney (33% compared to 47% each). Our reports showed a higher rate of 
dissemination to the lymph nodes (78% compared to 54%) and cardiac structures (56% to 34%). 
We do not believe the low number of identified necropsy reports suggests that this disease is less 
common in this region compared to California; we suspect that fewer animals are submitted for 
necropsy, possibly related to the availability of veterinary diagnostic laboratories in the area.  
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There were several limitations to our study design. While we created an online survey for 
ease of access and ideally to reach as many alpaca owners as possible, finding a good method to 
disseminate the survey proved difficult. As the precise location of alpaca herds in endemic 
regions is unknown, we relied heavily upon social media and word of mouth to distribute the 
survey link. Additionally, this was a retrospective study that relied upon the memory of the 
owners for up to the previous ten years. The survey stated that the animals reported in the study 
must be diagnosed by a veterinarian. However, veterinary records were not required to be 
submitted with the survey and anonymity meant we were unable to pursue further inquiry of the 
owner or the veterinarian that cared for the animals. This reporting mechanism may have 
resulted in over- or under-reporting of cases due to lack of understanding of owners, or lack of 
pursuing a diagnosis for sick or dead animals. Owner-reporting of therapies and therapeutic 
outcomes was both minimal and could lead to significant erroneous conclusions regarding the 
appropriateness or efficacy of agents. Rather, this information underscored our conclusion that 
research is needed to provide evidence-based treatment recommendations, preferably with 
outcome monitoring performed by veterinarians 
We also noted that participation in the survey was not consistent even within the highly 
endemic regions of Arizona. The average human cases per 100,000 people between 2010 and 
2014 were highest in Maricopa (211.9), Pinal (156.1), and Pima (132.0) counties ("Valley Fever: 
2015 Annual Report," 2015). Unfortunately, we received no survey responses from Pima 
County; however, six of the alpacas diagnosed by necropsy were from Pima County, along with 
two from Pinal and one from Santa Cruz counties. While it is not clear why we received no 
survey respondents from Pima County, it is likely Pima, Pinal, and Santa Cruz were represented 
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in the AZVDL cases due to proximity of the laboratory, located in Pima County, to the dead 
animals. Pinal and Santa Cruz counties are adjacent to Pima. 
Coccidioidomycosis is not a reportable disease in any veterinary species which inhibits the 
ability to monitor disease burden in animals, including SAC. In recent years, the human 
incidence of coccidioidomycosis has been increasing (Ampel, 2010); additionally, Coccidioides 
spp. have been identified in a region not previously known to be endemic for the fungi 
(Anastasia P. Litvintseva et al., 2015). These factors lead to an increasing concern for the 
potential effect of this disease in SAC. It would be worthwhile to pursue prospective studies of 
incidence, prevalence, and clinical presentation of coccidioidomycosis to educate veterinarians 
and owners about early detection, and to assess the pharmacokinetics of antifungal drugs to 
advise treatment of sick alpacas. 
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Table 1: Number of animals diagnosed by county 
State County No Sick/Total (%) 
AZ Cochise 2/20 (10%) 
  Coconino 0/2 (0%) 
  Maricopa 9/82 (11%) 
  Mohave 4/133 (3%) 
  Navajo 1/40 (3%) 
  Pinal 4/36 (11%) 
  Santa Cruz 3/57 (5%) 
  Yavapai 0/151 (0%) 
CA El Dorado 0/60 (0%) 
  Los Angeles 2/14 (14%) 
  Merced 1/75 (1%) 
  Riverside 2/8 (25%) 
  Tehama 1/45 (2%) 
  Ventura 1/42 (2%) 
NM Bernalillo 0/25 (0%) 
  Curry 1/70 (1%) 
  Sandoval 0/30 (0%) 
  Santa Fe 0/60 (0%) 
  Socorro 0/44 (0%) 
TX Crane 20/123 16%) 
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 Table 2: Frequency of reported clinical signs noted by owners of alpacas with 
coccidioidomycosis.  
Clinical Sign Frequency 
Weight loss 15 
Decreased energy 9 
Decreased appetite 8 
Coughing 6 
Lameness 5 
Inability to stand/walk 5 
Non-healing sores 3 
Fever 2 
Joint swelling 2 
Enlarged lymph nodes 2 
Fiber loss 2 
Nose bleed 1 
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Table 3: Alpaca necropsy report findings 
Animal 
Number Year Age Sex County Condition Lungs 
Lymph 
Nodes Liver Spleen Kidney Heart/Pericardium 
Other organs 
affected 
1 2016 3 yr M Pima poor + - + + - + 
Stifle periarticular 
tissue 
2 2009 17 mos M Pinal thin + + + + - + Pancreas 
3 2010 3 yr F Pinal unknown + + - - - - 
Mediastinal 
masses 
4 2010 8 mo M Pima unknown + + + - - -   
5 2013 adult F Pima poor + + - - - + 
 
6 2013 3 yr F Pima thin + + + + - +   
7 2009 10 yr M Santa Cruz good + + + - + +  Brain granulomas 
8 2008 6 yr F Pima unknown + + - - + -   
9 2008 3 yr F Pima poor + + + - + -   
     
Total: 9 7 6 3 3 5 
 
 
